Amarin Corp PLC(AMRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AMRN Amarin Corp PLC

Not Yet Opened 09-22 16:00:00 EDT

13.75

+0.27

+2.00%

盘后13.75

+0.000.00%

19:30 EDT

High13.90	Low13.52	Vol59.06K
Open13.52	D1 Closing13.48	Amplitude2.86%
Mkt Cap290.44M	Tradable Cap266.92M	Total Shares21.12M
T/O812.44K	T/O Rate0.30%	Tradable Shares19.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AMRN","market":"US","secType":"STK","nameCN":"Amarin Corp PLC","latestPrice":13.75,"timestamp":1790107200000,"preClose":13.48,"halted":0,"volume":59062,"hourTrading":{"tag":"盘后","latestPrice":13.75,"preClose":13.75,"latestTime":"19:30 EDT","volume":13,"amount":178.75,"timestamp":1790119800874,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.020029673590504418,"floatShares":19412400,"shares":21122834,"eps":-1.298704,"marketStatus":"Not Yet Opened","change":0.27,"latestTime":"09-22 16:00:00 EDT","open":13.515,"high":13.9,"low":13.515,"amount":812444.7642900001,"amplitude":0.028561,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.298704,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790150400000},"marketStatusCode":0,"adr":1,"adrRate":20,"listingDate":733640400000,"exchange":"NASDAQ","adjPreClose":13.48,"postHourTrading":{"tag":"盘后","latestPrice":13.75,"preClose":13.75,"latestTime":"19:30 EDT","volume":13,"amount":178.75,"timestamp":1790119800874,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.476676,"impliedVol":0.6636,"impliedVolPercentile":0.6255},"requestUrl":"/m/hq/s/AMRN","defaultTab":"news","newsList":[{"id":"2666559281","title":"European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559281","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666559281?lang=en_us&edition=fundamental","pubTime":"2026-09-10 23:34","pubTimestamp":1789054468,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were trending lower late Thursday morning, declining 0.41% to 1,938.57 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and accommodations booking site trivago , which advanced 1.6% and 1.1% respectively. They were followed by medical device maker EDAP TMS  and 3D printer company Materialise , which increased 1.2% and 0.8% respectively.The decliners from continental Europe were led by biotech firm Evaxion  and biopharmaceutical company DBV Technologies , which lost 5% and 2.7% respectively. They were followed by biotech firm BioNTech  and biopharmaceutical company Grifols , which were down 1.8% and 1.7% respectively.The gainers from the UK were led by software firm Endava  and biopharmaceutical company Akari Therapeutics , which were up 2% and 1.6% respectively. They were followed by telecommunications operator Vodafone Group  and pharmaceutical com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2468319806.SGD","BK4551","IEUR","LU1829250122.USD","LU2237443465.HKD","AKTX","COAL","BK4568","BK4082","BK4139","EVAX","DAVA","GRFS","MTLS","AFG","BNTX","AZNH","EPV","TRVG","BHP.AU","BHP","BK4532","LU0128525929.USD","DAVA.AU","LU0648005311.SGD","SLX","TRIB","AMRN","LU0320765992.SGD","LU2462157665.USD","AZN","BK4546","LU2237443622.USD","BK4134","BK4535","LU0708994859.HKD","BK4107","LU0310800379.SGD","PRNT","FOCL","BK4548","LU2456880835.USD","DBVT","LU0300736062.USD","BK4077","CLLS","LU0029864427.USD","LU0058720904.USD","VOD","BDRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324785","title":"Amarin Corporations Says Unit Signed Agreement and Duly Established the Joint Venture Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324785","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324785?lang=en_us&edition=fundamental","pubTime":"2026-09-08 18:47","pubTimestamp":1788864449,"startTime":"0","endTime":"0","summary":"Sept 8 (Reuters) - Amarin Corporations PCL::*UNIT  SIGNED AGREEMENT AND DULY ESTABLISHED THE JOINT VENTURE COMPANY*REGISTERED AND PAID-UP CAPITAL OF 50 MILLION BAHT*Further company coverage: AMARIN.BK","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nRSD9CSXj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663700879","title":"Amarin Highlights Reduce-it Post Hoc Study Linking Icosapent Ethyl to Lower Tissue Factor Levels, Fewer CV Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2663700879","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663700879?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:15","pubTimestamp":1788178541,"startTime":"0","endTime":"0","summary":"Amarin highlights REDUCE-IT post hoc study linking icosapent ethyl to lower tissue factor levels, fewer CV eventsAmarin highlighted new post hoc clinical analyses from REDUCE-IT presented at the ESC C","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL3w1KvF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00B3QW5Z07.USD","NDAQ","LU2095319765.USD","IE00BQXX3D17.EUR","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4585","AMRN","IE00BN0W2T93.GBP","SG9999014021.USD","BCDF","BK4112","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","SG9999014005.SGD","BK4588","SG9999014013.SGD","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","LU2210149790.SGD","IE00BQXX3F31.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662209884","title":"Amarin Says Post Hoc Reduce-it Analysis Shows Icosapent Ethyl Cardiovascular Benefit Persists After Treatment Stops","url":"https://stock-news.laohu8.com/highlight/detail?id=2662209884","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662209884?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:15","pubTimestamp":1787919320,"startTime":"0","endTime":"0","summary":"Amarin says post hoc REDUCE-IT analysis shows Icosapent Ethyl cardiovascular benefit persists after treatment stopsAmarin flagged a new post hoc REDUCE-IT “legacy” analysis presented at the European S","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLc9lK6f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","IE00BQXX3C00.GBP","LU2210149790.SGD","NDAQ","SG9999014005.SGD","LU0314104364.USD","BK4585","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014021.USD","IE00B3QW5Z07.USD","BK4588","AMRN","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","SG9999014039.USD","BCDF","IE00B64PRP62.GBP","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662098553","title":"New REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardiovascular Benefit Following Icosapent Ethyl Treatment Cessation in Adherent Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2662098553","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662098553?lang=en_us&edition=fundamental","pubTime":"2026-08-28 20:15","pubTimestamp":1787919300,"startTime":"0","endTime":"0","summary":"Data Supports Approximately 30% Relative Risk Reduction Among Highly Adherent Patients and Provides Evidence Consistent with a Potential Legacy Effect in Secondary Prevention Patients After Treatment ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/28/3352671/18362/en/new-reduce-it-legacy-analysis-presented-at-european-society-of-cardiology-esc-congress-2026-suggests-persistent-cardiovascular-benefit-following-icosapent-ethyl-treatment-cessation.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPV","HR","BK4203","BK4139","BK4585","SRET","TG","BK4153","AMRN","IPE","BK4082","CV","BK4225","BK4588","BK4090","CSII","VGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662748238","title":"European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2662748238","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662748238?lang=en_us&edition=fundamental","pubTime":"2026-08-26 23:13","pubTimestamp":1787757227,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were tracking lower late Wednesday morning, declining 0.46% to 1,977.10 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by accommodations booking site trivago  and biopharmaceutical company argenx , which advanced 2.9% and 2.6% respectively. They were followed by semiconductor company Sequans Communications  and 3D printer company Materialise , which rose 2% and 1.2% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and software firm SAP , which fell 3.5% and 2.7% respectively. They were followed by telecommunications company Ericsson  and pharmaceutical company Novo Nordisk , which lost 2.1% and 1.8% respectively.The gainers from the UK were led by biopharmaceutical companies Amarin  and Akari Therapeutics , which climbed 7.1% and 2.9% respectively. They were followed by tobacco company British American Tobacco  and biopharmaceuti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","BK4075","LU0648005311.SGD","BK4023","ERIC","LU1093756168.USD","BCYC","IE00B2B36J28.USD","NICO","ARGX","AKTX","LU0154236417.USD","BK4585","NVOC","IE0034235188.USD","BK4546","IE00BJJMRZ35.SGD","LU0320765992.SGD","AUTL","LU1093756325.SGD","LU1983260115.SGD","MREO","MTLS","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","BK4588","BK4007","BK4554","FMED","BK4599","TBXU","LU0084288595.USD","OZEM","LU0889565916.HKD","SAP","LU0109394709.USD","AMRN","LU2324357040.USD","DAVA","BK4515","BTI","BK4141","DBVT","NVOX","PPH","BDRX","BK4528","IE0009355771.USD","LU0072461881.USD","TRVG","BK4613","IE00BKVL7J92.USD","LU2543165471.USD","LU0823416689.USD","IE00BJT1NW94.SGD","BK4020","THNR","PRNT","BK4134","BK4591","BK4077","IE00BZ1G4Q59.USD","NVOH","NVO","SQNS","IE0002141913.USD","BK4139","LU0006061336.USD","BK4532","BK4505","LU0162691827.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661761882","title":"Amarin Flags New Reduce-it Analyses for Presentation at ESC Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661761882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661761882?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:15","pubTimestamp":1787573729,"startTime":"0","endTime":"0","summary":"Amarin flags new REDUCE-IT analyses for presentation at ESC Congress 2026Amarin flagged new REDUCE-IT analyses for presentation at the ESC Congress 2026 in Munich on Aug. 28-31.Data focus on adherence","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL17pDYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","LU2210150020.SGD","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BQXX3C00.GBP","LU0314104364.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4139","SG9999014039.USD","IE00BN0W2W23.USD","LU2210149790.SGD","NDAQ","IE00BQXX3F31.USD","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","BK4585","SG9999014013.SGD","AMRN","BK4588","SG9999014005.SGD","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661279661","title":"New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2661279661","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661279661?lang=en_us&edition=fundamental","pubTime":"2026-08-24 20:15","pubTimestamp":1787573700,"startTime":"0","endTime":"0","summary":"DUBLIN and BRIDGEWATER, N.J., Aug.  24, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a company committed to advancing the science of cardiovascular disease worldwide, today announced","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/24/3349705/18362/en/new-analyses-from-reduce-it-and-epa-mechanistic-data-to-be-presented-at-the-european-society-of-cardiology-esc-congress-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4153","IPE","LABU","BK4090","EPV","VGT","TG","AMRN","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661922362","title":"Amarin Price Target Announced at $13.00/Share by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2661922362","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661922362?lang=en_us&edition=fundamental","pubTime":"2026-08-22 03:20","pubTimestamp":1787340000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AMRN/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655146728","title":"Amarin Q2 FY26 Revenue Drops 42% to $42.2 Million; Gross Margin Narrows to 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655146728","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655146728?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:01","pubTimestamp":1785358883,"startTime":"0","endTime":"0","summary":"Amarin Q2 FY26 revenue drops 42% to $42.2 million; gross margin narrows to 30%Amarin posted Q2 revenue of $42.2 million, down 42% year over year.Product revenue fell 16% to $39.1 million, with U.S. re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL6DpTQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655403891","title":"Amarin Corporation PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2655403891","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655403891?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:12","pubTimestamp":1785337961,"startTime":"0","endTime":"0","summary":"Amarin Corporation PLC reports results for the quarter ended June 30 - Earnings SummaryAmarin Corporation PLCAMRN.OQreported quarterly adjusted earnings of 4 cents per share for the quarter ended June","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL8N43V2CD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655891767","title":"European Equities Traded in US as ADRs Ease in Wednesday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2655891767","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655891767?lang=en_us&edition=fundamental","pubTime":"2026-07-29 23:05","pubTimestamp":1785337507,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts eased late Wednesday morning with the S&P Europe Select ADR Index down 0.1% to 1,906.06.From continental Europe, the gainers were led by oil and gas company Eni  and energy company Equinor , which climbed 6.9% and 6.2%, respectively. They were followed by software firm SAP  and travel-booking company trivago , which increased 3% and 2.6%, respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications  and telecommunications company Nokia , which fell 4.8% and 3.6%, respectively. They were followed by lenders Banco Santander  and Banco Bilbao Vizcaya Argentaria , which dropped 2.5% and 2.3%, respectively.The gainers from the UK were led by software firm Endava  and oil and gas company BP , which rose 4.2% and 3.7%, respectively. They were followed by oil and gas company Shell  and biopharmaceutical company Amarin , which climbed 2.5% and 2.4%, respectively.The decliners from t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SLN","BP","SAN.AU","DRIP","FTXN","DIG","LU0648005311.SGD","BDRX","SHEL","BBVA","PXJ","SAP","BK4613","BK4134","EPV","USE","LU0006061336.USD","LNOK","SCHY","E","XES","AMRN","TRVG","DAVA.AU","BCS","BK4585","DBC","DAVA","LU0162691827.USD","BK4588","GUSH","SHEH","IEUR","IXC","AKTX","SAN","PXE","WTIU","DBE","SQNS","EQNR","NOK","DRLL","GSIB","IEO","VDE","ERX","BK4521","BPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655264864","title":"Ireland's Amarin Q2 Revenue Falls on Lower Licensing Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2655264864","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655264864?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:11","pubTimestamp":1785323507,"startTime":"0","endTime":"0","summary":"Ireland's Amarin Q2 revenue falls on lower licensing paymentsOverviewIreland-based cardiovascular drug maker's Q2 net revenue fell 42% yr/yr due to prior-year licensing paymentQ2 operating expenses dr","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nL1N43V0HC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655864904","title":"Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2655864904","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655864904?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:04","pubTimestamp":1785323075,"startTime":"0","endTime":"0","summary":"Amarin Corp (NASDAQ:AMRN) reported quarterly sales of $42.211 million which missed the analyst consensus estimate of $44.550 million by 5.25 percent.  This is a 41.97 percent decrease over sales of $72.740 million the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/07/60754344/amarin-corp-q2-sales-42-211m-miss-44-550m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655023861","title":"Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence","url":"https://stock-news.laohu8.com/highlight/detail?id=2655023861","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655023861?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUA5J9XJ8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","AMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861090","title":"Amarin Q2 Operating Expenses USD 27 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861090","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861090?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nPLX00D50Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654048247","title":"Amarin Corporation PLC Expected to Post a Loss of 1 Cent a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2654048247","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654048247?lang=en_us&edition=fundamental","pubTime":"2026-07-27 21:07","pubTimestamp":1785157627,"startTime":"0","endTime":"0","summary":"Amarin Corporation PLC <AMRN.OQ> expected to post a loss of 1cent a share - Earnings PreviewAmarin Corporation PLCAMRN.OQAMRN.Ois expected to  show a fall in quarterly revenue when it reports  results on July 29 for the period ending June 30 2026The Dublin Ireland-based   company is expected to report a 38.8% decrease in revenue to $44.55 million from $72.74 million a year ago, according to the estimate from one analyst, based on LSEG data.LSEG's mean analyst estimate for Amarin Corporation PLC is for a loss of 1 cent per share.The one available analyst rating on the shares is \"sell\".The mean earnings estimate of analysts was unchanged in the last three months. This summary was machine generated July 27 at 13:07 GMT.  All figures in US dollars unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nL8N43T15L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651468555","title":"Amarin Schedules Quarterly Results Release, Investor Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2651468555","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651468555?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:04","pubTimestamp":1784117052,"startTime":"0","endTime":"0","summary":"Amarin schedules quarterly results release, investor callAmarin schedules its Q2 2026 financial results release for July 29, 2026, ahead of the market open.Management conference call set for July 29, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDLbvtTYT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","IE00BKPKM429.USD","BCDF","NDAQ","LU0314104364.USD","LU2210149790.SGD","AMRN","SG9999014021.USD","SG9999014005.SGD","BK4588","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648268984","title":"European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2648268984","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648268984?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:13","pubTimestamp":1783005214,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were sharply higher late Thursday morning, advancing 2.21% to 1,927.62 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biopharmaceutical company Cellectis  and biotech firm Evaxion , which climbed 14% and 6.9% respectively. They were followed by biotech company BioNTech  and biopharmaceutical company DBV Technologies , which advanced 4.5% and 4.1% respectively.The only decliners from continental Europe were telecommunications company Nokia  and medical device maker EDAP , which were down 1% and 0.8% respectively.The gainers from the UK were led by biopharmaceutical companies Akari Therapeutics  and NuCana , which rose 8.6% and 6.6% respectively. They were followed by biotech firm Autolus Therapeutics  and pharmaceutical company Silence Therapeutics , which were up 4.8% and 3.7% respectively.The only decliners from the UK and Ireland were biopharmaceutical companies Biodexa Pharmaceuti","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4020","BK4551","IE00BMPRXR70.SGD","EPV","BK4107","BDRX","LNOK","AMRN","CLLS","BK4588","BK4585","BK4117","AKTX","BNTX","AUTL","BK4007","LU0006061336.USD","BK4547","SLN","EVAX","BK4139","NCNA","AFG","BK4548","BK4568","DBVT","NOK","FOCL","BK4082","IEUR","BK4535","IE00BMPRXN33.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648642295","title":"Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape","url":"https://stock-news.laohu8.com/highlight/detail?id=2648642295","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648642295?lang=en_us&edition=fundamental","pubTime":"2026-07-01 04:15","pubTimestamp":1782850500,"startTime":"0","endTime":"0","summary":"Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated TriglyceridesDUBLIN, Ireland a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3320122/18362/en/Amarin-Reaffirms-the-Proven-Guideline-Recommended-Role-of-VASCEPA-Icosapent-Ethyl-in-an-Evolving-Triglyceride-Treatment-Landscape.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TG","BK4153","BK4585","AMRN","IPE","LABU","BK4588","BK4139","BK4090","WAC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amarincorp.com","stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":-0.0241},{"period":"3month","weight":-0.1621},{"period":"6month","weight":-0.0627},{"period":"1year","weight":-0.1057},{"period":"ytd","weight":-0.0147}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0547},{"period":"6month","weight":0.1989},{"period":"1year","weight":0.1598},{"period":"ytd","weight":0.1341}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.121922},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.050693},{"month":3,"riseRate":0.484848,"avgChangeRate":0.002821},{"month":4,"riseRate":0.424242,"avgChangeRate":0.057152},{"month":5,"riseRate":0.382353,"avgChangeRate":-0.011028},{"month":6,"riseRate":0.5,"avgChangeRate":0.005489},{"month":7,"riseRate":0.242424,"avgChangeRate":-0.032454},{"month":8,"riseRate":0.545455,"avgChangeRate":0.060342},{"month":9,"riseRate":0.424242,"avgChangeRate":0.075054},{"month":10,"riseRate":0.375,"avgChangeRate":-0.048639},{"month":11,"riseRate":0.5625,"avgChangeRate":0.109863},{"month":12,"riseRate":0.4375,"avgChangeRate":-0.023149}],"exchange":"NASDAQ","name":"Amarin Corp PLC","nameEN":"Amarin Corp PLC","securityTypeName":"DR","adrRate":"1:20"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amarin Corp PLC(AMRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amarin Corp PLC(AMRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amarin Corp PLC,AMRN,Amarin Corp PLC股票,Amarin Corp PLC股票老虎,Amarin Corp PLC股票老虎国际,Amarin Corp PLC行情,Amarin Corp PLC股票行情,Amarin Corp PLC股价,Amarin Corp PLC股市,Amarin Corp PLC股票价格,Amarin Corp PLC股票交易,Amarin Corp PLC股票购买,Amarin Corp PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amarin Corp PLC(AMRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amarin Corp PLC(AMRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction